Fc receptor binding proteins

Abstract

This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

1 - 89 . (canceled) 
     
     
         90 : A method of reducing the concentration of undesired antibodies in an individual comprising administrating to the individual a therapeutically effective dose of an antibody or a fragment thereof, wherein the antibody comprises a heavy chain (HC) immunoglobulin variable domain sequence and a light chain (LC) immunoglobulin variable domain sequence; and wherein
 the HC comprises:
 a HC CDR1 comprising the amino acid sequence EYAMG (SEQ ID NO:144) or VYAMG (SEQ ID NO:156), 
 a HC CDR2 comprising the amino acid sequence SIGSSGGQTKYADSVKG (SEQ ID NO:145) or SIGSSGGPTKYADSVKG (SEQ ID NO:157), and 
 a HC CDR3 comprising the amino acid sequence LSTGELY (SEQ ID NO:146), LSIRELV (SEQ ID NO:158), LSIVDSY (SEQ ID NO:164), LSLGDSY (SEQ ID NO:170), or, LAIGDSY (SEQ ID NO:176); and 
   the LC comprises:
 a LC CDR1 comprising the amino acid sequence TGTGSDVGSYNLVS (SEQ ID NO:141), 
 a LC CDR2 comprising the amino acid sequence GDSQRPS (SEQ ID NO:142), and 
 a LC CDR3 comprising the amino acid sequence CSYAGSGIYV (SEQ ID NO:143). 
   
     
     
         91 - 110 . (canceled) 
     
     
         111 : The method of  claim 90 , wherein the antibody or a fragment thereof is administered in a pharmaceutically acceptable carrier. 
     
     
         112 : The method of  claim 90 , wherein the individual is a human. 
     
     
         113 : The method of  claim 90 , wherein the antibody or fragment thereof is administered with an adjuvant. 
     
     
         114 : The method of  claim 90 , wherein the undesired antibody is natalizumab. 
     
     
         115 : The method of  claim 90 , wherein the undesired antibody is non-self Human Leukocyte Antigen. 
     
     
         116 : The method of  claim 115 , wherein the administered antibody or fragment thereof is administered in connection with organ transplant.